REVIEW ARTICLES

Metforminul în managementul diabetului gestaţional

 Metformin in the management of gestational diabetes

First published: 12 iulie 2022

Editorial Group: MEDICHUB MEDIA

DOI: 10.26416/ObsGin.70.2.2022.6682

Abstract

Gestational diabetes mellitus (GDM) is a common pregnancy complication detected especially in the second or third trimester of gestation, with an increasing prevalence over recent decades. Pathophysiologically, GDM develops as a consequence of adative metabolic changes, overlapping a previously unknown pancreatic β-cell dysfunction. The major risk factors for GDM include obesity/overweight, advanced maternal age, family history of insulin resistance and/or diabetes, previous history of gestational diabetes and macrosomia, and the presence of polycystic ovary syndrome (PCOS). Many European countries, including Romania, use selective screening (based on risk factors) as a tool for the detection of GDM. As hyperglycemia is associated with a number of severe maternal and fetal complications, the management of patients with GDM involves a multidisciplinary team consisting of obstetricians, maternal-fetal medicine specialists and diabetes specialists with experience in treating pregnant women. Insulin is the first-choice treatment if lifestyle optimization methods fail. In recent years, attention has focused on oral antidiabetics, specifically on the efficacy and safety of their use as an alternative to insulin treatment. Metformin is an oral antidiabetic of the biguanide class, the first-line treatment for type 2 diabetes outside pregnancy. Due to reduced maternal complications, low cost and increased compliance, the use of metformin in the treatment of GDM is increasing. Most trials have not reported an increased rate of maternal complications in patients treated with metformin. Short-term fetal effects are favorable, but for long-term effects, the results are still unclear. Most medical societies consider metformin safe and effective, but due to a lack of data on the long-term safety profile, it is only recommended for use in cases where insulin therapy is not an option.
 

Keywords
gestational diabetes, metformin, insulin, pregnancy

Rezumat

Diabetul gestaţional (DG) este o complicaţie comună a sarcinii, apărută în special în al doilea sau al treilea trimestru, cu o prevalenţă în continuă creştere. Din punct de vedere fiziopatologic, boala apare ca o consecinţă a modificărilor metabolice adaptative suprapuse peste o disfuncţie, anterior necunoscută, a celulelor β pancreatice. Principalii factori de risc asociaţi cu diabetul zaharat gestaţional sunt obezitatea/supraponderea, vârsta maternă avansată, istoricul familial pozi­tiv pentru diabet, antecedente personale de diabet gestaţional, macrosomie fetală la sarcini anterioare sau sindromul ovarelor micropolichistice. Multe ţări din Europa, printre care şi România, folosesc screeningul selectiv (bazat pe prezenţa factorilor de risc) pentru a detecta DG. Deoarece hiperglicemia se asociază cu o serie de complicaţii materne şi fetale severe, managementul pacientelor cu DG implică o echipă multidisciplinară formată din obstetrician, specialist în medicina materno-fetală şi diabetolog cu experienţă în tratarea pacientei gravide. Insulina este prima opţiune de tratament în cazul eşecului metodelor de optimizare a stilului de viaţă. În ultimii ani, atenţia s-a concentrat asupra antidiabeticelor orale, mai exact asupra eficacităţii şi siguranţei folosirii lor ca o alternativă la tratamentul cu insulină. Metforminul este un antidiabetic oral din clasa biguanidelor, prima linie de tratament a diabetului zaharat de tip 2 în afara sarcinii. Datorită complicaţiilor materne reduse, costului redus şi complianţei crescute, utilizarea metforminului în tratamentul DG este în creştere. Majoritatea trialurilor nu au raportat o creştere a ratei de complicaţii materne la pacientele tratate cu metformin. Efectele fetale pe termen scurt sunt favorabile, însă în ceea ce priveşte efectele pe termen lung, rezultatele sunt încă neclare. Cele mai multe societăţi medicale consideră metforminul sigur şi eficient, însă din cauza lipsei datelor privind profilul de siguranţă pe termen lung, se recomandă utilizarea acestuia doar în cazurile în care insulinoterapia nu este o opţiune.

Introduction

Gestational diabetes mellitus (GDM) is defined as glucose intolerance with onset or first recognition during pregnancy. It is a common pregnancy complication and, according to the International Diabetes Federation (IDF), it affects approximately 16.7% of pregnancies worldwide and 15% in Europe, with an increasing prevalence over recent decades due to advanced maternal age and maternal obesity(1). GDM generally develops in the second or third trimester of pregnancy, as a consequence of adaptive metabolic changes, overlapping a previously unknown pancreatic b-cell dysfunction(2).

Pathophysiology

During a healthy pregnancy, several physiological changes occur in order to support the demands of the growing fetus. These include adaptations to the cardiovascular, renal, respiratory, hematologic and metabolic systems. One important metabolic adaptation concerns the insulin sensitivity. In early pregnancy, insulinemia and insulin sensitivity are increased, corresponding to an anabolic phase necessary for the development of the embryo. During the second and third trimesters of gestation, a state of insulin resistance is induced by placental hormones (placental lactogen, placental growth hormone, estrogen, progesterone), leptin, cortisol and growth hormone. As a result, maternal blood glucose is elevated and thus facilitates its transport across the placenta, supporting the rapid growth of the fetus. In order to maintain normal blood glucose levels, animal studies have shown that healthy pregnant women compensate through hypertrophy and hyperplasia of pancreatic b-cells, as well as by increased glucose-stimulated insulin secretion (GSIS). In women who develop GDM, pancreatic b-cells fail to keep up with the increased insulin demand, resulting in hyperglycemia(3).

Risk factors

The major risk factors for GDM include overweight/obesity (BMI>25 kg/m2), advanced maternal age (above 35 years old), family history of insulin resistance and/or diabetes, previous history of gestational diabetes and macrosomia, and the presence of polycystic ovary syndrome (PCOS)(4).

Screening and diagnosis

Many European countries, including Romania, use selective screening (based on risk factors) as a tool for the detection of gestational diabetes mellitus. Because the incidence of type 2 DM is high in our country, all pregnant women are screened for overt type 2 DM at their first prenatal visit, using the fasting plasma glucose threshold of 126 mg/dl for diagnosis. Women at risk and without overt diabetes have 75 g OGTT at 24-28 weeks. The positive diagnostic consists of at least one of the following criteria: fasting plasma glucose ≥92 mg/dl; 1h≥180 mg/dl; 2h≥153 mg/dl(5,6).

Complications

Hyperglycemia is associated with serious maternal and fetal complications. Women with GDM are at high risk of gestational hypertension, preeclampsia and caesarean section. The long-term consequences are: an increased risk of developing type 2 diabetes,  future cardiovascular disease and recurrent gestational diabetes mellitus(2). The most common fetal/neonatal complications include macrosomia, polyhydramnios, shoulder dystocia, preterm birth, neonatal hypoglycemia, respiratory distress and perinatal death. Intrauterine exposure to GDM also has a long-term impact on offspring health – studies have demonstrated reduced insulin sensitivity and an increased risk of type 2 diabetes, metabolic syndrome, hypertension in adolescence and overweight/obesity compared with the general population(7).

Treatment

The management of patients with gestational diabetes mellitus involves a multidisciplinary team of obstetricians, maternal-fetal medicine specialists and diabetes specialists with experience in treating pregnant women. The main goal is glycemic control in order to diminish the risk of the associated adverse pregnancy outcomes. International guidelines recommendations on glycemic targets are fasting level ≤95 mg/dl and either 1-hour postprandial ≤140 mg/dl or 2-hour postprandial ≤120 mg/dl(8). Lifestyle intervention, comprising dietary modification, physical activity and weight control, is essential in the management of GDM. If good glycemic control is not achieved, then the pharmacologic treatment should be considered. Historically, insulin has been the preferred medication for treating GDM refractory to lifestyle changes and it continues to be the first-choice agent recommended by the American Diabetes Association (ADA). Over the last decades, there has been a great interest in whether oral antidiabetics (metformin, glyburide) could be used safely and effectively in women with GDM to avoid the need for insulin injections. Several studies have demonstrated that metformin is noninferior to insulin for pregnancy outcomes, and many international guidelines recommend it as an alternative to insulin, but long-term safety data are insufficient(9).

Metformin

Metformin is a biguanide – an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes mellitus, lowering both basal and postprandial plasma glucose. It inhibits hepatic gluconeogenesis and intestinal glucose absorption and improves insulin sensitivity by increasing peripheral glucose uptake and utilization(10).

Metformin is the first-line medication for the treatment of type 2 diabetes, and the most commonly prescribed drug for this condition worldwide. Compared to insulin, its risk for hypoglycemia is low, it is not associated with weight gain, it is easy to administer and it’s cheaper. The most common adverse effect is related to the digestive system, including diarrhea, nausea, vomiting and increased flatulence. It is not recommended for use in renal or hepatic impairment due to concern for accumulation leading to lactic acidosis, which is a rare complication(10,11).

The renal clearance of metformin is significantly increased in the second and third trimesters of gestation, as a consequence of increased renal plasma flow and glomerular filtration during pregnancy. Therefore, patients may require higher doses for adequate glycemic control(12). Moreover, it is excreted into breast milk but the amount is clinically insignificant and studies have shown no effect on glycemic values of infants after breastfeeding(13).

Unlike insulin, which needs an insulin-antibody complex to cross the placental barrier, metformin can freely traverse the placenta, with levels in fetal circulation similar to the maternal ones(14). Due to the potential for acidosis or growth restriction, ADA cautions that metformin should not be used in women with placental insufficiency, hypertension, preeclampsia or at risk for intrauterine growth restriction(15). Nonetheless, due to the maternal safety profile, as well as its low cost and good compliance among patients, the use of metformin in GDM is increasing.

Interest in the role of metformin in GDM gained ground with the Metformin in Gestational Diabetes (MiG) trial published in 2008. MiG trial compared metformin versus insulin in 751 women diagnosed with GDM between 20 and 33 weeks of gestation. There was no difference bet­ween the two groups regarding neonatal complications, including respiratory distress, need for phototherapy, birth trauma, low Apgar score or prematurity. The incidence of neonatal hypoglycemia and maternal weight gain was significantly lower with metformin. However, the incidence of preterm births (<37 weeks of gestation) was higher in the metformin group. In a questionnaire, a significantly large number of women responded that they would opt for metformin again (76%) than insulin (27%), suggesting greater patient acceptability(16).

Effects on maternal outcomes

Most trials do not report an increase in adverse maternal outcomes for GDM patients treated with metformin compared to insulin. According to several recent meta-analyses, metformin is rather beneficial because it is associated with lower maternal weight gain and with a lower risk of pregnancy-induced hypertension(17-19). There is evidence that metformin is also associated with a reduced risk of preeclampsia(20,21). Although glycemic control is comparable to insulin or glyburide, metformin has some additional advantages, including a lower risk of maternal hypoglycemia, a lower cost of therapy and less need for intensive self-monitoring blood glucose levels. Moreover, in contradiction to some old studies(22), recent meta-analyses did not demonstrate any increase in rates of preterm deliveries in women with gestational diabetes mellitus or type 2 diabetes who are using metformin(19,23).

Effects on fetal outcomes

The effect of metformin on short-term fetal outcomes has been largely favorable. It was  associated with lower incidence of macrosomia and LGA babies (large for gestational age) and with a low risk of neonatal hypoglycemia, including severe neonatal hypoglycemia(19,23). In addi­tion, the rate of neonatal intensive care unit admissions appears to be lower for metformin than insulin(24)

Information on long-term outcomes for offspring exposed to metformin is still limited. The MiG TOFU trial (The Metformin in Gestational Diabetes: The Offspring Follow-Up) showed that the 2-year-old offspring from mothers treated with metformin had larger measures of subcutaneous fat (subscapular, biceps skinfolds), but the overall body fat was the same as in children whose mothers were treated with insulin alone(25). Also, the 9-year-old infants exposed to metformin were heavier and had a higher waist-to-height ratio and waist circumference than those exposed to insulin. Total and abdominal body fat percentage and metabolic measures (fasting glucose, triglyceride, insulin, insulin resis­tance, HbA1c, cholesterol, liver transaminases, leptin and adiponectin) were similar in both groups(26). Regarding the neurophysiological development, currently available data showed no difference in motor, social or linguistic development for children prenatally exposed to metformin compared to insulin(27).

Current recommendations

Metformin is not currently approved by the American Food and Drug Administration (FDA) for the management of diabetes in pregnancy and it is placed in category B of safety, which means that animal reproduction studies did not demonstrate any risk to the fetus, but there is a lack of well-documented studies on pregnant women. Metformin remains the second-line pharmacotherapy choice for many international medical associations, such as the International Diabetes Federation (IDF), the American College of Obstetricians and Gynecologists (ACOG), the American Diabetes Association (ADA) and the International Federation of Gynecology and Obstetrics (FIGO)(28).

Conversely, the British National Institute for Health and Care Excellence (NICE) recommends metformin as first-line therapy for women whose blood glucose levels do not stabilize after 1-2 weeks of diet and exercise. Insulin is recommended only in cases where metformin is contraindicated or unacceptable to the patient(29). Also, the Society for Maternal-Fetal Medicine (SMFM) states that metformin is a reasonable and safe first-line pharmacologic alternative to insulin, recognizing that one-half of women will still require insulin to achieve glycemic control(30).

Conclusions

All these considered, metformin is an effective and well-tolerated glucose-lowering agent with a well-defined mechanism of action. It remains a reliable first-line treatment for type 2 diabetes in most patients. Current animal and human data indicate that metformin is safe and effective in the management of GDM and may improve the immediate pregnancy outcomes. It reduces maternal weight gain during pregnancy and the risk of pregnancy-induced hypertension. In infants, it reduces the incidence of severe hypoglycemia and the incidence of macrosomia. There is no evidence of an increased risk of congenital fetal anomalies when using metformin.

Moreover, some medical associations consider metformin safe and effective as first-line medication in gestational diabetes mellitus when the diet regimen is insufficient, but due to the lack of long-term safety data related to fetal exposure, most of them restrict its use to those cases in which there is no possibility of insulin treatment.

 

Conflict of interests: The authors declare no conflict of interests.

Bibliografie

  1. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract [Internet]. 2022;183:109119. Available from: https://doi.org/10.1016/j.diabres.2021.109119

  2. Johns EC, Denison FC, Norman JE, Reynolds RM. Gestational Diabetes Mellitus: Mechanisms, Treatment, and Complications. Trends Endocrinol Metab [Internet]. 2018;29(11):743–54. Available from: https://doi.org/10.1016/j.tem.2018.09.004

  3. Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The pathophysiology of gestational diabetes mellitus. Int J Mol Sci. 2018;19(11):1–21. 

  4. Dobjanschi C, Miulescu RD. Risk factors for gestational diabetes – an update. Rom J Diabetes, Nutr Metab Dis. 2015;22(2):201–7. 

  5. Panaitescu AM, Peltecu G. Gestational diabetes. Obstetrical perspective. Acta Endocrinol (Copenh). 2016;12(3):331–4. 

  6. Diagnostic Criteria and Classification of Hyperglycaemia First Detected in Pregnancy. Diabetes Res Clin Pract. 2014;103(3):341–363. 

  7. Wu CS, Nohr EA, Bech BH, Vestergaard M, Olsen J. Long-term health outcomes in children born to mothers with diabetes: A population-based cohort study. PLoS One. 2012;7(5):1–7. 

  8. ACOG Practice Bulletins. Gestational diabetes mellitus. ACOG Practice Bulletin No. 190. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2018;131(180):e49–64. 

  9. Care D, Suppl SS. Management of diabetes in pregnancy: Standards of medical care in diabetes-2020. Diabetes Care. 2020;43(January):S183–92. 

  10. Drugs.com. METFORMIN [Internet]. Drugs.com. 2022. Available at: https://www.drugs.com/pro/metformin.html#s-34070-3

  11. Flory J, Lipska K. Metformin in 2019. JAMA. 2019;321(19):1926–7. 

  12. Hughes RCE, Gardiner SJ, Begg EJ, Zhang M. Effect of pregnancy on the pharmacokinetics of metformin. Diabet Med. 2006;23(3):323–6. 

  13. Briggs GG, Ambrose PJ, Nageotte MP, Padilla G, Wan S. Excretion of metformin into breast milk and the effect on nursing infants. Obstet Gynecol. 2005;105(6):1437–41. 

  14. Eyal S, Easterling TR, Carr D, Umans JG, Miodovnik M, Hankins GDV, et al. Pharmacokinetics of metformin during pregnancy. Drug Metab Dispos. 2010;38(5):833–40. 

  15. Care D, Suppl SS. 15. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes - 2022. Diabetes Care. 2022;45(January):S232–43. 

  16. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. Metformin versus insulin for the treatment of gestational diabetes. Obstet Gynecol Surv. 2008;63(10):616–8. 

  17. Zhu B, Zhang L, Fan YY, Wang L, Li XG, Liu T, et al. Metformin versus insulin in gestational diabetes mellitus: a meta-analysis of randomized clinical trials. Ir J Med Sci. 2016;185(2):371–81. 

  18. Liang H, Ma S, Xiao Y, Tan H. Comparative efficacy and safety of oral antidiabetic drugs and insulin in treating gestational diabetes mellitus. Medicine (Baltimore). 2017;96(38):e7939. 

  19. Butalia S, Gutierrez L, Lodha A, Aitken E, Zakariasen A, Donovan L. Short- and long-term outcomes of metformin compared with insulin alone in pregnancy: a systematic review and meta-analysis. Diabet Med. 2017;34(1):27–36. 

  20. Ainuddin J, Karim N, Hasan AA, Naqvi SA. Metformin versus insulin treatment in gestational diabetes in pregnancy in a developing country. A randomized control trial. Diabetes Res Clin Pract [Internet]. 2015;107(2):290–9. Available from: http://dx.doi.org/10.1016/j.diabres.2014.10.001.

  21. Alqudah A, McKinley MC, McNally R, Graham U, Watson CJ, Lyons TJ, et al. Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis. Diabet Med. 2018;35(2):160–72. 

  22. Poolsup N, Suksomboon N, Amin M. Efficacy and safety of oral antidiabetic drugs in comparison to insulin in treating gestational diabetes mellitus: A meta-analysis. PLoS One. 2014;9(10):e109985. 

  23. Farrar D, Simmonds M, Bryant M, Sheldon TA, Tuffnell D, Golder S, et al. Treatments for gestational diabetes: A systematic review and meta-analysis. BMJ Open. 2017;7(6):e015557. 

  24. Kitwitee P, Limwattananon S, Limwattananon C, Waleekachonlert O, Ratanachotpanich T, Phimphilai M, et al. Metformin for the treatment of gestational diabetes: An updated meta-analysis. Diabetes Res Clin Pract [Internet]. 2015;109(3):521–32. Available from: http://dx.doi.org/10.1016/j.diabres.2015.05.017.

  25. Rowan JA, Rush EC, Obolonkin V, Battin M, Wouldes T, Hague WM. Metformin in gestational diabetes: The offspring follow-up (MiG TOFU) – Body composition at 2 years of age. Diabetes Care. 2011;34(10):2279–84. 

  26. Rowan JA, Rush EC, Plank LD, Lu J, Obolonkin V, Coat S, et al. Metformin in gestational diabetes: The offspring follow-up (MiG TOFU): Body composition and metabolic outcomes at 7-9 years of age. BMJ Open Diabetes Res Care. 2018;6(1):1–12. 

  27. Xu Q, Xie Q. Long-term effects of prenatal exposure to metformin on the health of children based on follow-up studies of randomized controlled trials: a systematic review and meta-analysis. Arch Gynecol Obstet [Internet]. 2019;299(5):1295–303. Available from: https://doi.org/10.1007/s00404-019-05124-w

  28. Skibinska M, Zurawska-Klis M, Krekora M, Cypryk K. Metformin administration during pregnancy - current insight. Ginekol Pol. 2021;92(1):46–50. 

  29. National Institute for Health and Care Excellence. Diabetes in pregnancy: management from preconception to the postnatal period. NICE [Internet]. 2015;(February):2–65. Available from: http://www.ncbi.nlm.nih.gov.ez.srv.meduniwien.ac.at/pubmed/25950069.

  30. Society of Maternal-Fetal Medicine (SMFM) Publications Committee. SMFM Statement: Pharmacological treatment of gestational diabetes. Am J Obstet Gynecol. 2018;218(5):B2-B4. doi:10.1016/j.ajog.2018.01.041.

Articole din ediţiile anterioare

ORIGINAL ARTICLES | Ediţia 1 70 / 2022

Obesity and pregnancy

Cristina Mihaela Ormindean, Răzvan  Ciortea, Cristian Iuhaș, Radu F. Mocan-Hognogi, Dan Mihu

În ultimele două decenii, obezitatea şi supraponderea au crescut semnificativ, devenind probleme de sănătate publică la nivel mondial. Datele din l...

24 mai 2022
REVIEW ARTICLES | Ediţia 1 68 / 2020

Actualităţi în managementul afecţiunilor tiroidiene la femei în perioada sarcinii

Teodora Turtă, Melinda Matyas, Lucia Procopciuc, Daniel Mureşan, Gabriela Caracostea

Afecţiunile tiroidiene sunt printre cel mai frecvent întâlnite patologii la femeile aflate la vârsta fertilă. Homeostazia tiroidiană este important...

16 martie 2020
REVIEW ARTICLES | Ediţia 4 68 / 2020

Myasthenia gravis şi sarcina

Crisanda Vîlciu, Bogdan Marius Istrate

Myasthenia gravis (MG) is an autoimmune disorder affecting nearly 1 million individuals worldwide, being diagnosed typically in the second and thir...

23 decembrie 2020
EDITORIAL | Ediţia 4 69 / 2021

Impactul dializei asupra parametrilor clinici şi paraclinici în insuficienţa renală acută asociată cu sarcina sau cu perioada post-partum

Daniela-Cătălina Meca, Sorin Vasilescu, Conf. Univ. Dr. Claudia Mehedinţu, Monica Mihaela Cîrstoiu

Insuficienţa renală acută rămâne o provocare ca diagnostic şi management, având în vedere incidenţa redusă a cazurilor raportate. Luând în consider...

20 decembrie 2021